Corbus Pharmaceuticals
CRBP
101 hedge funds and large institutions have $164M invested in Corbus Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 15 reducing their positions, and 9 closing their positions.
200% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 9
173% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 15
22% more funds holding
Funds holding: 83 → 101 (+18)
8% more capital invested
Capital invested by funds: $152M → $164M (+$12.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.29% less ownership
Funds ownership: 1.51% → 1.22% (-0.29%)
35% less call options, than puts
Call options by funds: $3.32M | Put options by funds: $5.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$6.79M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.7M |
| 3 |
GAI
General American Investors
New York
|
+$4.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.85M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$23.3M |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$11.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.54M |
| 4 |
BlackRock
New York
|
-$801K |
| 5 |
Millennium Management
New York
|
-$757K |
CRBP Hedge Fund Activity: Q1 2019 in Review
101 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2019, worth a combined $164M — up 8.5% from $152M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CRBP positions and 9 closed out — a net gain of 18 holders — while 41 added to existing stakes and 15 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $6.79M. The largest seller was ETF Managers Group, exiting entirely with an estimated $23.3M sold.
- 101 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2019, up from 83 in Q4 2018.
- Funds reported $164M of Corbus Pharmaceuticals stock for Q1 2019, up 8.5% quarter-over-quarter.
- 27 funds opened new Corbus Pharmaceuticals positions in Q1 2019 and 9 closed out, a net change of +18 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2019 was Knoll Capital Management, an estimated $6.79M added.
- The largest Corbus Pharmaceuticals seller in Q1 2019 was ETF Managers Group, an estimated $23.3M sold.
Based on aggregated 13F filings for Q1 2019.